Abstract：
BACKGROUND: Mucin-producing cholangiocarcinoma (MPCC) was rare biliary tract malignancy. Studies regarding this type of cholangiocarcinoma (CCA) were limited, particularly the survival outcome. We aim to evaluate the survival rate, median survival time after surgery among CCA patients and to determine the association between MPCC and survival.
OBJECTIVE: To evaluate survival rate, median survival time after surgery among cholangiocarcinoma patients and to determine the association between mucin-producing cholangiocarcinoma and survival.
METHODS: CCA patients who underwent surgery between 2013 and 2020 from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand were included in the study. The MPCC was based on pathological findings after surgery. The survival of CCA patients was verified through medical records and civil registration. Survival rates and median survival time since the date of CCA surgery and its 95% confidence intervals (CI) were estimated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by adjusted hazard ratios (AHR) and their 95% CI.
RESULTS: Of 1,249 CCA patients which constituted 24,593 person-months, 687 died at the completion of the study. The overall incidence rate was 2.79 per 100 patients per month, the median survival time was 21.77 months (95% CI: 19.87 - 23.84), and the 5-year survival rate was 28.29% (95% CI: 24.99 - 31.67). From these patients, 210 (16.81%) were MPCC, the incidence rate was 1.81 per 100 patients per month, median survival time was 41.21 months (95% CI: 26.16 - 81.97), and 5-year survival rate was 44.69% (95% CI: 32.47 - 56.16). MPCC were 35% less likely to died compared with non-MPCC (AHR = 0.65; 95% CI: 0.50 - 0.84).
CONCLUSIONS: Our study revealed that CCA patients with MPCC had longer survival times and higher survival rates than those without MPCC. This classification will lead to appropriate treatment guidelines for CCA patients.
OBJECTIVE: To evaluate survival rate, median survival time after surgery among cholangiocarcinoma patients and to determine the association between mucin-producing cholangiocarcinoma and survival.
METHODS: CCA patients who underwent surgery between 2013 and 2020 from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand were included in the study. The MPCC was based on pathological findings after surgery. The survival of CCA patients was verified through medical records and civil registration. Survival rates and median survival time since the date of CCA surgery and its 95% confidence intervals (CI) were estimated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by adjusted hazard ratios (AHR) and their 95% CI.
RESULTS: Of 1,249 CCA patients which constituted 24,593 person-months, 687 died at the completion of the study. The overall incidence rate was 2.79 per 100 patients per month, the median survival time was 21.77 months (95% CI: 19.87 - 23.84), and the 5-year survival rate was 28.29% (95% CI: 24.99 - 31.67). From these patients, 210 (16.81%) were MPCC, the incidence rate was 1.81 per 100 patients per month, median survival time was 41.21 months (95% CI: 26.16 - 81.97), and 5-year survival rate was 44.69% (95% CI: 32.47 - 56.16). MPCC were 35% less likely to died compared with non-MPCC (AHR = 0.65; 95% CI: 0.50 - 0.84).
CONCLUSIONS: Our study revealed that CCA patients with MPCC had longer survival times and higher survival rates than those without MPCC. This classification will lead to appropriate treatment guidelines for CCA patients.
摘要：
背景：产粘蛋白的胆管癌（MPCC）是罕见的胆道恶性肿瘤。关于这种类型的胆管癌（CCA）的研究是有限的，尤其是生存的结果。我们的目标是评估生存率，CCA患者手术后的中位生存时间，并确定MPCC与生存之间的关系。
目的：为了评估生存率，胆管癌患者手术后的中位生存时间，并确定产生粘蛋白的胆管癌与生存之间的关系。
方法：从胆管癌筛查和护理计划（CASCAP）在2013年至2020年期间接受手术的CCA患者，泰国东北部被纳入研究。MPCC基于手术后的病理结果。CCA患者的生存通过医疗记录和民事登记得到证实。估计自CCA手术之日起的生存率和中位生存时间及其95％置信区间（CI）。进行多重cox回归以评估与生存相关的因素，这些因素通过调整后的风险比（AHR）及其95％CI进行量化。
结果：在构成24,593人-月的1,249例CCA患者中，687人在研究完成时死亡。总发病率为2.79/100患者每月，中位生存时间为21.77个月(95%CI:19.87-23.84),5年生存率为28.29%(95%CI:24.99-31.67)。从这些病人身上,210人（16.81%）为MPCC，发病率为每月每100名患者1.81名，中位生存时间为41.21个月(95%CI:26.16-81.97),5年生存率为44.69％（95％CI：32.47-56.16）。与非MPCC相比，MPCC死亡的可能性降低了35％（AHR=0.65；95％CI：0.50-0.84）。
结论：我们的研究表明，患有MPCC的CCA患者比没有MPCC的患者具有更长的生存时间和更高的生存率。这种分类将导致CCA患者的适当治疗指南。
目的：为了评估生存率，胆管癌患者手术后的中位生存时间，并确定产生粘蛋白的胆管癌与生存之间的关系。
方法：从胆管癌筛查和护理计划（CASCAP）在2013年至2020年期间接受手术的CCA患者，泰国东北部被纳入研究。MPCC基于手术后的病理结果。CCA患者的生存通过医疗记录和民事登记得到证实。估计自CCA手术之日起的生存率和中位生存时间及其95％置信区间（CI）。进行多重cox回归以评估与生存相关的因素，这些因素通过调整后的风险比（AHR）及其95％CI进行量化。
结果：在构成24,593人-月的1,249例CCA患者中，687人在研究完成时死亡。总发病率为2.79/100患者每月，中位生存时间为21.77个月(95%CI:19.87-23.84),5年生存率为28.29%(95%CI:24.99-31.67)。从这些病人身上,210人（16.81%）为MPCC，发病率为每月每100名患者1.81名，中位生存时间为41.21个月(95%CI:26.16-81.97),5年生存率为44.69％（95％CI：32.47-56.16）。与非MPCC相比，MPCC死亡的可能性降低了35％（AHR=0.65；95％CI：0.50-0.84）。
结论：我们的研究表明，患有MPCC的CCA患者比没有MPCC的患者具有更长的生存时间和更高的生存率。这种分类将导致CCA患者的适当治疗指南。
